Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Giannakou, ChristinaPark, Margriet V D Z
Bosselaers, Irene E M
de Jong, Wim H
van der Laan, Jan Willem
van Loveren, Henk
Vandebriel, Rob J
Geertsma, Robert E
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls.Published in
Interdiscip Rev Nanomed Nanobiotechnol 2020; 12(5):e1633PMID
32266791ae974a485f413a2113503eed53cd6c53
10.1002/wnan.1633
Scopus Count
Collections
Related articles
- A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements.
- Authors: Giannakou C, Park MV, de Jong WH, van Loveren H, Vandebriel RJ, Geertsma RE
- Issue date: 2016
- The ICH S8 immunotoxicity guidance. Immune function assessment and toxicological pathology: autonomous or synergistic methods to predict immunotoxicity?
- Authors: Spanhaak S
- Issue date: 2006 Jul
- Regulatory aspects of immunotoxicology.
- Authors: Schulte A, Ruehl-Fehlert C
- Issue date: 2006 Jul
- Nanomedicinal products: a survey on specific toxicity and side effects.
- Authors: Brand W, Noorlander CW, Giannakou C, De Jong WH, Kooi MW, Park MV, Vandebriel RJ, Bosselaers IE, Scholl JH, Geertsma RE
- Issue date: 2017
- Approaches and considerations for the assessment of immunotoxicity for environmental chemicals: a workshop summary.
- Authors: Boverhof DR, Ladics G, Luebke B, Botham J, Corsini E, Evans E, Germolec D, Holsapple M, Loveless SE, Lu H, van der Laan JW, White KL Jr, Yang Y
- Issue date: 2014 Feb